Find Clinical Trials

Search thousands of clinical trials by condition, location, and eligibility criteria

0
Total Trials
0
Trials Recruiting
0
Conditions Covered
0
Locations Worldwide
0
Sponsors
Clinical trial guides

Browse trials by condition

View all guides

Browse by location

Showing 12 of 4281 trials
Conditions Treatment-resistant Depression (TRD), Ma...
Phase NA
Enrollment 40
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The primary objective of this study is to evaluate the clinical efficacy of moderate-dose transcranial photobiomodulation (t-PBM) at different frequencies (10 Hz and 40 Hz) in patients with treatment-resistant depression (TRD). It further aims to explore the differential efficacy across various symptom subtypes, with a particular focus on the somatic symptom-dominant subtype. Additionally, this study will collect paired-pulse neurophysiological parameters (e.g., the ratio of cortical inhibition to excitation) to preliminarily explore the neural mechanisms underlying the modulation of cortical excitability by t-PBM intervention, and to analyze their correlation with the magnitude of clinical symptom improvement. The specific aims of this study are as follows: To evaluate the differential efficacy of t-PBM at varying frequencies (10 Hz vs. 40 Hz) in improving clinical depressive symptoms (as measured by scales such as HAM-D and MADRS). To investigate the therapeutic response to t-PBM in patients with the somatic symptom-dominant depression subtype, analyzing its potential suitability for targeting specific symptoms. To explore the changes in paired-pulse TMS parameters (e.g., SICI, ICF, and LICI) before and after t-PBM treatment, gaining preliminary insights into the potential association between its cortical modulatory effects and clinical outcomes.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Double

Interventions / Regimen

  • Device: transcranial photobiomodulation — Participants will receive active transcranial photobiomodulation (tPBM) stimulation at a frequency of 10 Hz. The device delivers near-infrared light targeting the prefrontal cortex. Each treatment session lasts for 20 minutes, administered twice a week for four consecutive weeks (totaling 8 sessions).

Primary Outcomes

  • Change in the 17-item Hamilton Depression Rating Scale (HDRS-17) Total Score (Baseline, Week 4 (Post-treatment), and Week 8 (1-month follow-up after treatment))
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-01-06
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 40 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Taipei Veterans General Hospital, Taiwan
Contact Information
Study Contact:
Jia-Shyun Jeng
+886900015031
jscheng2@vghtpe.gov.tw
Jia-Shyun Jeng
+886-900-015-031
jscheng2@vghtpe.gov.tw
Taipei Veterans General Hospital
Interventions
  • Device: transcranial photobiomodulation — Participants will receive active transcranial photobiomodulation (tPBM) stimulation at a frequency of 10 Hz. The device delivers near-infrared light targeting the prefrontal cortex. Each treatment session lasts for 20 minutes, administered twice a week for four consecutive weeks (totaling 8 sessions).
Study Locations (1 sites)
Taipei Veterans General Hospital, Taipei, 11217 Taiwan
Eligibility Criteria
Inclusion Criteria: Must have a current diagnosis of Major Depressive Disorder (MDD). The clinical severity must be evaluated by a psychiatrist as moderate or above, defined as a Clinical Global Impression-Severity (CGI-S) score \> 4 and a 17-item Hamilton Depression Rating Scale (HDRS-17) total score ≥ 18. Must be currently receiving stable antidepressant treatment for at least four weeks but showing inadequate response (treatment-resistant). This study will be conducted as an add-on therapy. Must have full behavioral capacity, normal intellectual functioning, and the ability to comprehend and sign the informed consent form. Exclusion Criteria: Individuals diagnosed with Bipolar Disorder or Schizophrenia. Individuals with current or recent Substance Use Disorder. History of organic brain lesions (e.g., neurodegenerative diseases, epilepsy, stroke) or any medical conditions affecting central nervous system function. Individuals with abnormal intellectual functioning based on clinical judgment (e.g., suspected intellectual disability, severe learning difficulties). Individuals who are currently pregnant (due to limited evidence regarding the safety of tPBM during pregnancy). Any other condition that, in the investigator's judgment, would render the participant unable to cooperate, unsuitable for the study, or unwilling to sign the informed consent.
Conditions Type 2 Diabetes
Phase PHASE2
Enrollment 300
Locations 25 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Blood sugar levels are controlled by insulin, a hormone made by cells in the pancreas. After a meal, carbohydrates are broken down into glucose which is absorbed from the intestine into the blood leading to a rise in glucose (blood sugar) which triggers the secretion of insulin. Insulin binds to cells in several tissues including liver, muscle, and fat, triggering cells to take up glucose and bring the blood glucose level back to normal. A high blood sugar level is known as diabetes. The most common form of diabetes, type 2 diabetes, is caused by insulin resistance; that is, a reduced ability of insulin to stimulate glucose uptake into cells. The body compensates for insulin resistance by making more insulin; type 2 diabetes occurs when the pancreas can no longer make enough insulin to control blood glucose. The high blood glucose and insulin levels lead to long-term complications such as heart attacks, kidney failure, reduced sensation and poor circulation in the feet and legs. High insulin levels also increase the incidence of cancers, stroke, and dementia. Reducing blood glucose levels with oral medications and insulin reduces risk of diabetic complications. There are several types of oral medications available for treating diabetes; however, they do not always control blood glucose adequately. In addition, these drugs have complications and are not used to treat insulin resistance and prediabetes - a condition when blood glucose is higher than normal but not high enough to be classified as diabetes. Prediabetes often progresses to diabetes over a period of months or years. Effective and safe treatments for insulin resistance may prevent the onset of diabetes or even reverse diabetes if diagnosed in its early stages before substantial damage to the pancreas has occurred. HP-211 is a botanical extract whose active ingredients are derived from herbs and vegetables present in normal diets. HP-211 has been shown in laboratory studies in cell culture, in animal studies, and in a previous Phase 1 study to enhance the ability of insulin to stimulate glucose uptake into cells. Thus, HP-211 may reduce the blood glucose and circulating insulin levels of subjects with type 2 diabetes after a meal. HP-211 may also reduce glucose and insulin responses to a greater extent in insulin-resistant as compared to insulin-sensitive subjects. Subjects will take 0, 1, 2 or 3 tablets of HP-211 in the morning and evening for 90 days. Hemoglobin A1c (HbA1c, or "A1c"), a measure of the average amount of glucose present in the blood, will be measured during the trial period.

Design

Study type: Interventional Phases: Phase2 Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: Quadruple

Interventions / Regimen

  • Drug: HP-211 — HP-211 is an investigational botanical extract derived from Cichorium endivia var. latifolium, Lactuca sativa, and Artemisia dracunculus.
  • Drug: Placebo — Matching placebo administered orally twice daily (BID).

Primary Outcomes

  • Change from Baseline in Hemoglobin A1c (HbA1c) (After 12 weeks of treatment.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE2
Status: Recruiting
Start Date: 2023-02-03
Completion: 2026-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Housey Healthcare ULC
Contact Information
Study Contact:
Housey Study Info
(248) 663-7000
StudyInfo@housey.com
818-253-8966
aroobalingam@allianceclinicalnetwork.com
Alliance Clinical Canoga Park (Hope Clinical Research)
Hessam Aazami, MD
Alliance Clinical Canoga Park (Hope Clinical Research)
Interventions
  • Drug: HP-211 — HP-211 is an investigational botanical extract derived from Cichorium endivia var. latifolium, Lactuca sativa, and Artemisia dracunculus.
  • Drug: Placebo — Matching placebo administered orally twice daily (BID).
Study Locations (25 sites)
Alliance Clinical Canoga Park (Hope Clinical Research), Canoga Park, California 91303 United States
Universal Axon Clinical Research, Doral, Florida 33166 United States
Velocity Clinical Research New Smyrna Beach, Edgewater, Florida 32132 United States
Southwest General Healthcare Center, Fort Myers, Florida 33907 United States
Avantis Clinical Research, Miami, Florida 33155 United States
IMIC Research, Miami, Florida 33176 United States
South Broward Research, Miramar, Florida 33027 United States
David Kavtaradze MD InC, Cordele, Georgia 31015 United States
AMR Clinical - El Dorado, El Dorado, Kansas 67042 United States
Tandem Clinical Research (Interspond), Marrero, Louisiana 70072 United States
Eligibility Criteria
Key Inclusion Criteria: * Have type 2 diabetes for greater than 3 months and no longer than 5 years by history prior to entering the trial, based upon ADA disease diagnostic criteria. * Have an HbA1c \> 6.5% and ≤ 10% as determined by the central lab at Visit 1 (Screening). * Have been on a stable maximum dose of metformin for at least 3 months prior to entering the study or have been on stable therapy of diet and exercise only for at least 3 months. Stable treatment is defined as no change in treatment or dose in the last 3 months. Key Exclusion Criteria: * Have known type 1 diabetes. * Diabetic complications * Have taken any oral (other than metformin) or injectable treatment (insulin or GLP-1 RA classes or other) for type 2 diabetes currently or for greater than a 4 week duration previously. Previous treatment must have been stopped at least 3 months prior to screening * Systolic blood pressure greater than 150 mmHg or a diastolic blood pressure greater than 100 mmHg at Visit 1 on average after three supine measurements, or a known history of renal artery stenosis. * At baseline, the QT interval corrected by Fridericia (QTcF) ECG findings (\>450 msec for males and \>470 msec for females), left bundle branch block, or cardiac arrhythmia requiring medical or surgical treatment within 6 months prior to Visit 1 on the ECG.
Conditions Breast Cancer
Phase Not Applicable
Enrollment 44
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The advances in early detection coupled with improvements in treatments have led to an ever-increasing number of breast cancer survivors. New methods to improve outcomes, including strategies aimed at improving the quality of life and reducing the risk of other diseases, may represent valid additions to the currently available treatment options. Interventions targeting diet, weight and physical activity can reduce the risk of cancer occurrence, prevent cancer recurrence, improve survival and the quality of life. This is an observational, prospective study aimed at evaluating the effects of physical activity on the quality of life of patients with early stage hormone receptor positive breast cancer receiving adjuvant hormonal therapy and adhering to a physical activity program lasting for a total of 12 weeks organized by ANDOS onlus (Associazione Italiana Donne Operate al Seno).

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Change in Quality of Life as measured by the EORTC QLQ-C30 questionnaire. (Up to 6 months after the end of the physical activity program)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-04-03
Completion: 2027-12-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: Not specified
Enrollment: 44 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Centro di Riferimento Oncologico - Aviano
Contact Information
Study Contact:
Mattia Garutti
0434659092
mattia.garutti@cro.it
Mattia Garutti, MD
0434659092
mattia.garutti@cro.it
Centro di Riferimento Oncologico di Aviano
Mattia Garutti, MD
Centro di Riferimento Oncologico di Aviano
Interventions
N/A
Study Locations (1 sites)
Centro di Riferimento Oncologico di Aviano, Aviano, Pordenone 33081 Italy
Eligibility Criteria
Inclusion Criteria: * Patients with early stage (I-IIIa) hormone receptor-positive breast cancer receiving adjuvant endocrine therapy * Female patients ≥18 years of age * Written informed consent must be obtained before any study-related assessment is performed * Participation to the Medicina and Sport physical activity program organized by Andos Pordenone Exclusion Criteria: * Patients with early hormone receptor negative breast cancer * Patients with early hormone receptor positive breast cancer receiving chemotherapy * Patients with advanced/metastatic breast cancer. * Patients receiving active treatment for secondary primary tumors (excluding basal cell carcinoma or in situ neoplasias). * Patients with history of vertebral and/or femoral fractures * Patients with CVDs not optimally controlled by medical therapy
Conditions TNBC - Triple-Negative Breast Cancer
Phase Not Applicable
Enrollment 300
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

A real-world, multicenter, prospective study to evaluate the patient-reported outcome in Chinese patients who received sacituzumab govitecan or chemotherapy of the physician's choice for metastatic breast cancer progressing on first-line treatment

Design

Study type: Observational Observational model: Cohort Time perspective: Retrospective

Primary Outcomes

  • Mean change from baseline in the EORTC QLQ-C30 GHS/QOL score. (12 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-05-15
Completion: 2029-06-15
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 300 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Fudan University
Contact Information
Study Contact:
Biyun Wang Professor
+86 13701748410
pro_wangbiyun@163.com
Biyun Wang
+86 18017312387
pro_wangbiyun@163.com
Fudan University Shanghai Cancer Center
Interventions
N/A
Study Locations (1 sites)
Fudan University Shanghai Cancer Center, Shanghai, Shanghai Municipality 200032 China
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 to 75 years. 2. Patients have been diagnosed with metastatic HER2 negative breast cancer. HER2 status were determined locally by immunohistochemistry (IHC) of patients' primary or metastatic tumor sections. HER2-negative status was defined by IHC staining 0 to 1+ or fluorescence in situ hybridization ratio \<2.0 if IHC 2+ or IHC not performed. 3. The metastatic disease was confirmed by clinical, imaging, histological, or cytological measures, including unresectable locally advanced breast cancer, de novo stage IV breast cancer, and recurrent metastatic breast cancer. 4. ECOG-PS ≤2 5. For patients with triple-negative breast cancer (TNBC): at least 1 line of systemic therapy in the metastatic setting; for patients with HR+/HER2- breast cancer: prior treatment with endocrine therapy and CDK4/6 inhibitors, and at least 1 line of systemic therapy in the metastatic setting. 6. At least one evaluable lesion by CT or MRI according to RECIST 1.1. 7. Willing to accept the treatment by the investigator based on the patient's preference, physical condition, prior treatment history, and financial circumstances. 8. Willing to use contraceptive measures during the study period. 9. Willing and able to complete electronic questionnaires/scales on a smartphone, tablet, or other electronic device. 10. All patients can provide an informed consent before enrolment and data collection. Exclusion Criteria: 1. Insufficient bone marrow, hepatic, or renal function, defined as: * Bone marrow: White blood cell count \< 3.0 × 10⁹/L, or absolute neutrophil count \< 1.5 × 10⁹/L, or platelet count \< 75 × 10⁹/L, or hemoglobin \< 8.0 g/dL. * Hepatic function: Total bilirubin \> 1.5 × upper limit of normal (ULN), or ALT/AST \> 3.0 × ULN (or \> 5.0 × ULN in the presence of liver metastases). * Renal function: Serum creatinine \> 1.5 × ULN, or creatinine clearance \< 50 mL/min. 2. History of other malignancies or hematologic malignancies. 3. Hypersensitivity to the study treatment drugs. 4. Systemic anti-tumor therapy (including chemotherapy, radiotherapy, immunotherapy, etc.) within 2 weeks prior to study drug administration. 5. Treatment with an investigational product within 4 weeks before the first treatment. 6. Presence of any toxicity from prior therapy (excluding alopecia) ≥ Grade 2 according to CTCAE version 5.0, prior to study drug administration. 7. Systemic inflammatory diseases, including but not limited to systemic lupus erythematosus, juvenile chronic arthritis, spondyloarthropathy, Crohn's disease, ulcerative colitis, psoriatic arthritis, or active vasculitis. 8. Severe psychiatric or neurological disorders, including but not limited to schizophrenia, depression, mania, Alzheimer's disease, myasthenia gravis, seizure disorders, or known conditions that may provoke seizures. 9. Pregnant or breastfeeding women.
Conditions Hypertension, Elderly (People Aged 65 or...
Phase NA
Enrollment 60
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

This feasibility study aims to evaluate the effects of dynamic strength training and isometric strength training on cardiovascular health indicators, mental health, and neuromuscular fitness in older adults with hypertension. Participants will be randomly assigned to one of the two training modalities and will complete supervised exercise sessions throughout the intervention period. The study will provide preliminary evidence regarding the safety, acceptability, and potential impact of each training modality on health outcomes in this population.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Behavioral: Dynamic Strength Training — The experimental group will perform dynamic strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group movements, initially 2 sets of 15 repetitions (Borg 4-6), progressing to 3 sets of 10 repetitions (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for \~30 minutes at moderate intensity.
  • Behavioral: Isometric Strength Training — The experimental group will perform isometric strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group contractions, initially 2 sets of 60 seconds (Borg 4-6), progressing to 3 sets of 40 seconds (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for \~30 minutes at moderate intensity.
  • Behavioral: No supervised intervention Control — This group serves as a control and will not perform any structured exercise program.

Primary Outcomes

  • Recruitment rate (Baseline and 6 weeks)
  • Adherence to training sessions (During 6 weeks)
  • Retention rate (During 6 weeks)
  • Fidelity to exercise protocol (Duiring 6 weeks)
  • Acceptability of the intervention (During 6 weeks)
  • Occurrence of adverse events (During 6 weeks)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-03-01
Completion: 2027-12-31
Eligibility
Age: 60 Years and older
Sex: ALL
Volunteers: false
Enrollment: 60 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Raphael Mendes Ritti Dias
Principal Investigators:
  • Raphael M Ritti-Dias, PhD (STUDY_CHAIR) - University of Nove de Julho
Contact Information
Study Contact:
Adão Luis Monte L Monte, Ms
+55 11 94666 5213
adaoluiz8@outlook.com
Raphael M Ritti-Dias, PhD
+5519999406878
raphaelritti@gmail.com
Interventions
  • Behavioral: Dynamic Strength Training — The experimental group will perform dynamic strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group movements, initially 2 sets of 15 repetitions (Borg 4-6), progressing to 3 sets of 10 repetitions (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for \~30 minutes at moderate intensity.
  • Behavioral: Isometric Strength Training — The experimental group will perform isometric strength exercises targeting major muscle groups, progressing in intensity and volume over the 6 weeks. Exercises include 8 major muscle group contractions, initially 2 sets of 60 seconds (Borg 4-6), progressing to 3 sets of 40 seconds (Borg 5-7) from week 5. Participants will also be advised to perform non-supervised walking 3-5 times per week for \~30 minutes at moderate intensity.
  • Behavioral: No supervised intervention Control — This group serves as a control and will not perform any structured exercise program.
Study Locations (1 sites)
Uninove, São Paulo, São Paulo 01525-000 Brazil
Eligibility Criteria
Inclusion criteria: * Diagnosis of arterial hypertension and currently taking antihypertensive medication * Age 60 years or older * Resting blood pressure below 160/95 mmHg * No high cardiovascular risk according to the American College of Sports Medicine criteria (for participants with type 2 diabetes, glycemic control with fasting glucose \<100 mg/dL and postprandial glucose \<140 mg/dL) * Not participating in a structured exercise program for more than three months * No cognitive or functional limitations that prevent participation in the exercise program Exclusion Criteria * Presence of acute illnesses, such as influenza, sinusitis, gastroenteritis, urinary tract infection, fever, inflammatory processes, or any clinical condition requiring rest or that may compromise safety during assessments or training. * Decompensated clinical conditions, including: Blood pressure spikes, Chest pain, Uncontrolled arrhythmias, Shortness of breath at rest, Asthma exacerbations, Decompensated diabetes mellitus, characterized by Persistently elevated blood glucose levels (fasting glucose \> 180 mg/dL or postprandial glucose \> 250 mg/dL) * Irregular use of medication * Any unstable clinical condition or condition that represents additional risk for the practice of physical exercise.
Conditions Breast-Conserving Surgery
Phase NA
Enrollment 172
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

The goal of this clinical trial is to learn if a novel intraoperative fluorescence-guided system (EndoSCell Scanner) can help surgeons more accurately remove all cancerous tissue during breast-conserving surgery in female patients aged 18 years or older, with primary breast cancer. The main questions it aims to answer are: * Does the use of the EndoSCell Scanner system lower the rate of secondary surgeries needed due to positive cancer margins after the initial operation? * How accurate is the EndoSCell Scanner system in detecting residual cancer cells on the walls of the surgical cavity during the operation? Researchers will compare the surgical outcomes using the EndoSCell Scanner guidance to the expected outcomes from standard surgical practice without this technology to see if the system is effective. Participants will: * Receive their planned breast-conserving surgery (lumpectomy). * Have their surgical cavity scanned with the EndoSCell Scanner device after the main tumor is removed. * Have additional tissue removed from the cavity wall if the scanner indicates a potential cancer residue.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Diagnostic Masking/blinding: Double

Interventions / Regimen

  • Device: EndoSCell Scanner (ES Scanner) System — The EndoSCell Scanner (ES Scanner) is an intraoperative fluorescence imaging system used during breast-conserving surgery to provide real-time, cellular-level visualization of the surgical cavity wall. During the surgery, after removing the main tumor specimen and the standard circumferential cavity shave margins, the cavity wall is locally stained with sodium fluorescein and methylene blue. Then, the ES Scanner probe is placed on the cavity wall tissue and the blue light is used to detect the fluorescence patterns related to residual cancer cells. The system processes and displays these images in real time, highlighting the areas that may contain residual cancer cells. This visual guidance aims to assist surgeons in precisely removing additional tissue margins ( "therapeutic shaves" ) from specific suspicious cavity wall locations during the initial surgery, in order to achieve a negative (no cancer) surgical margin in the first operation.

Primary Outcomes

  • The rate of positive margins on final pathological testing (From the date of the initial lumpectomy (Day 0) until the receipt of the final postoperative pathology report and surgical decision, assessed up to 30 days post-surgery.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-04-01
Completion: 2027-03-31
Eligibility
Age: 18 Years and older
Sex: FEMALE
Volunteers: false
Enrollment: 172 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Guangdong Provincial People's Hospital
Contact Information
Study Contact:
Kun Wang
020-83827812
wangkun@gdph.org.cn
Liulu Zhang
020-83827812
zhangliulu@gdph.org.cn
Dr. Zhang, MD
020-83827812-80420
zhangliulu@gdph.org.cn
Guangdong Provincial People's Hospital
Interventions
  • Device: EndoSCell Scanner (ES Scanner) System — The EndoSCell Scanner (ES Scanner) is an intraoperative fluorescence imaging system used during breast-conserving surgery to provide real-time, cellular-level visualization of the surgical cavity wall. During the surgery, after removing the main tumor specimen and the standard circumferential cavity shave margins, the cavity wall is locally stained with sodium fluorescein and methylene blue. Then, the ES Scanner probe is placed on the cavity wall tissue and the blue light is used to detect the fluorescence patterns related to residual cancer cells. The system processes and displays these images in real time, highlighting the areas that may contain residual cancer cells. This visual guidance aims to assist surgeons in precisely removing additional tissue margins ( "therapeutic shaves" ) from specific suspicious cavity wall locations during the initial surgery, in order to achieve a negative (no cancer) surgical margin in the first operation.
Study Locations (1 sites)
Guangdong Provincial People's Hospital, Guangzhou, Guangdong 510080 China
Eligibility Criteria
Inclusion Criteria: 1. Pathologically confirmed diagnosis of primary invasive breast cancer, ductal carcinoma in situ (DCIS), or invasive breast cancer with a DCIS component. Acceptable diagnostic methods include core needle biopsy or fine-needle aspiration biopsy. 2. Female, age ≥ 18 years. 3. Scheduled to undergo breast-conserving surgery for the malignant breast lesion. 4. Willing and able to comply with the study procedures and follow-up. 5. Has provided written informed consent. 6. No other uncontrolled serious medical conditions aside from the cancer diagnosis (see Exclusion Criteria for details). 7. Adequate organ and bone marrow function, defined as: * White blood cell count \> 3,000/μL * Platelet count \> 75,000/μL * Total bilirubin ≤ institutional upper limit of normal (ULN) * AST (SGOT) / ALT (SGPT) \< 2.5 × institutional ULN * Serum creatinine ≤ 1.5 mg/dL, OR creatinine clearance \> 60 mL/min/1.73 m² (for participants with serum creatinine levels above institutional ULN) 8. ECOG performance status of 0 or 1. Exclusion Criteria: 1. Pregnancy or lactation. 2. Suspected pregnancy. 3. Prior injection of ICG or other fluorescent dyes for sentinel lymph node mapping on the day of surgery, before the planned lumpectomy cavity scan with the study device. 4. Unresolved adverse events from previous medications or diagnostic agents. 5. Uncontrolled hypertension, defined as persistent systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg. Patients with known hypertension must be stable on medication within these limits. 6. History of allergy to any oral or intravenous contrast agent. 7. Uncontrolled comorbidities, including but not limited to: * Active infection * Symptomatic congestive heart failure * Unstable angina pectoris * Cardiac arrhythmia * Hospitalization for COPD or asthma within the past 12 months * Psychiatric illness/social situations that would limit compliance with study requirements. 8. Any condition where, in the investigator's judgment, participation would not be in the best interest of the participant. 9. Planned re-excision lumpectomy due to positive margins from a prior surgery performed before enrollment. 10. Prior surgical history in the ipsilateral breast, including breast cancer surgery, mastectomy, breast reconstruction, or implant placement.
Conditions Chronic Rhinosinusitis With Nasal Polyps...
Phase Not Applicable
Enrollment 110
Locations 10 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

ARES is a multi-centre, retrospective-prospective, non-comparative and non-interventional (observational) cohort study involving primary and secondary data collection within real-world settings of participants who have initiated tezepelumab (no more than 4 weeks before inclusion) for treatment of CRSwNP (with or without comorbid asthma).

Design

Study type: Observational Observational model: Other Time perspective: Other

Primary Outcomes

  • 1. Change in endoscopic status of CRSwNP based on NPS (time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation)
  • 2. Change in a nasal congestion status based on Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22) (time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation)
  • 3. Change in endoscopic status of CRSwNP based on NPS (time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation)
  • 4. Change in a nasal congestion status based on Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22) (time points to measure: baseline and at Weeks 4, 24 and 52 following tezepelumab initiation)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2025-12-25
Completion: 2028-03-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 110 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: AstraZeneca
Contact Information
Study Contact:
AstraZeneca Clinical Study Information Center
1-877-240-9479
information.center@astrazeneca.com
Interventions
N/A
Study Locations (10 sites)
Research Site, Kazan', Russia
Research Site, Kemerovo, Russia
Research Site, Krasnoyarsk, Russia
Research Site, Lermontov, Russia
Research Site, Moscow, Russia
Research Site, Rostov-on-Don, Russia
Research Site, Ryazan, Russia
Research Site, Saint-Petesburg, Russia
Research Site, Ulyanovsk, Russia
Research Site, Yekaterinburg, Russia
Eligibility Criteria
Inclusion Criteria: 1. Male or female participants aged 18 years or older at the time of signing the ICF. 2. Diagnosis of CRSwNP established for at least 52 weeks prior to tezepelumab initiation. 3. Availability of participants' medical records for at least 52 weeks prior to tezepelumab initiation, including history of sCS use / nasal polyps surgery (or information about contraindications / intolerance to). 4. Prescribed and initiated treatment with tezepelumab according to SmPC and local market reimbursement criteria. A period between treatment initiation and enrolment should be no more than 4 weeks. 5. The severity of CRSwNP consistent with need for surgery as defined by total NPS ≥ 5 (at least 2 for each nostril) at the enrollment. 6. Nasal Blockage score as part of SNOT-22 (NBS-SNOT-22) ≥ 3 at the enrollment. 7. SNOT-22 total score ≥ 30 at enrollment or up to 12 weeks before enrollment. 8. Currently receive care from specialist physicians (e.g., otolaryngologist) at the Investigator's or sub-Investigator's site. 9. Provision of signed and dated written informed consent. 10. Participants are able to read, understand and complete the questionnaires required by the protocol. Exclusion Criteria: 1. Any contraindication to tezepelumab as per the approved product SmPC in Russia or in the opinion of the Investigator. 2. Administration of concurrent biologic drug for CRSwNP / asthma since the index date, except for stable allergen immunotherapy (defined as a stable dose and regimen at the time of enrolment). Enrolment of patients who were switched from other biologic(s) to tezepelumab is allowed, and an acceptable timeframe since the last prior biologic drug is ≥ 60 days. The number of participants with prior biologic treatment (switching to tezepelumab) should be targeted at 20% or less. 3. Participation in an observational study that might, in the Investigator's opinion, influence the assessment for the current study, or participation in an interventional clinical trial in the last 3 months. 4. Pregnancy or lactation period.
Conditions Liver Cirrhosis, Portal Hypertension
Phase Not Applicable
Enrollment 45
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Portal vein thrombosis is defined as non-tumoural obstruction of the portal vein or one of its branches. Its incidence is 0.7 to 2.7 per 100,000 patient-years in the general population, and 4.6 per 100 patient-years in patients with cirrhosis. Histological modificaitions fo the portal vein wall and haemostatic changes have been described in cirrhotic patients. The contribution of these changes, both systemic and local, to the development of portal vein thrombosis is debated. One of the hypotheses put forward on the genesis of portal vein thrombosis is as follows: certain bacterial translocations from the digestive tract, promoted by portal hypertension, contribute to endothelial activation resulting in the release of von Willebrand factor and factor VIII, as well as platelet activation and the coagulation cascade, which is dysregulated by cirrhosis and underlying changes in haemostatic balance. Inflammatory phenomena and NETosis may also be involved. Studies suggest that cirrhotic patients have lesions of the glycocalyx located in the portal area, which may be involved in the development of portal vein thrombosis. Patients with cirrhosis may benefit from the placement of a transjugular intrahepatic portosystemic shunt (TIPS). During the TIPS placement procedure, blood is drawn from the internal jugular vein and the portal vein, allowing for parallel biological analyses. The assumption of this study is that haemostasis and inflammation are disrupted differently at the systemic and portal levels in cirrhotic patients.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Area Under the Curve (AUC) of primary hemostasis assessed by T-TAS®01 at 10 minutes (At 10 minutes of perfusion during the T-TAS®01 primary hemostasis assessment procedure)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-03-09
Completion: 2027-06-09
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 45 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Stéphanie ROULLET stephanie.roullet@aphp.fr, PhD
145596949
stephanie.roullet@aphp.fr
STEPHANIE ROULLET, PhD
145596949
stephanie.roullet@aphp.fr
Hôpital Paul Brousse
Interventions
N/A
Study Locations (1 sites)
Hôpital Paul Brousse, Villejuif, 94800 France
Eligibility Criteria
Inclusion Criteria: * Adult patients (aged ≥18 years) covered by a social security scheme or entitled beneficiaries * Patients followed for a cirrhotic condition at Paul Brousse Hospital and undergoing placement of a TIPS (transjugular intrahepatic portosystemic shunt) Exclusion Criteria: * Patient unwilling to participate in the study * Patient with a contraindication to TIPS placement * Patient with a known hemostatic disorder unrelated to cirrhosis * Patient receiving treatment that interferes with hemostasis and has not been discontinued for the procedure * Patient receiving systemic corticosteroid therapy * Patient under legal protection * Patient not covered by a social security scheme
Conditions Alveolar Soft Part Sarcoma, Renal Cell C...
Phase PHASE1
Enrollment 30
Locations 3 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what effects GCAR1 has on selected cancers

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: Fludarabine — Assigned at enrollment
  • Drug: Cyclophosphamide — Assigned at enrollment
  • Biological: GCAR1 — Dose escalation

Primary Outcomes

  • To determine the recommended phase II dose (RP2D), defined as the next lower dose below the maximum administered dose, of GPNMB directed CAR T cell therapy (3 years)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-08-30
Completion: 2033-09-01
Eligibility
Age: 15 Years and older
Sex: ALL
Volunteers: false
Enrollment: 30 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Canadian Cancer Trials Group
Collaborators: University of Calgary, Canadian Institutes of Health Research (CIHR), BioCanRx
Principal Investigators:
  • Mona Shafey (STUDY_CHAIR) - Tom Baker Cancer Centre, Calgary, Alberta, Canada
Contact Information
Study Contact:
Laura Pearce
613-533-6430
lpearce@ctg.queensu.ca
Mariam Jafri
613-533-6430
mjafri@ctg.queensu.ca
Mona Shafey
403 944-8047
Arthur J.E. Child Comprehensive Cancer Centre
Interventions
  • Drug: Fludarabine — Assigned at enrollment
  • Drug: Cyclophosphamide — Assigned at enrollment
  • Biological: GCAR1 — Dose escalation
Study Locations (3 sites)
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta T2N 5G2 Canada
University Health Network, Toronto, Ontario M5G 2M9 Canada
The Research Institute of the McGill University, Montreal, Quebec H4A 3J1 Canada
Eligibility Criteria
Inclusion Criteria: * Archival tumour specimen must be positive for GPNMB with high expression by immunohistochemistry (central laboratory testing). * Histologically and/or cytologically confirmed diagnosis of one of the following tumours that is advanced/ metastatic/ recurrent or unresectable, for which no curative therapy exists. * alveolar soft part sarcoma * renal cell carcinoma (excluding clear cell) * triple negative breast cancer (ER, PR and HER-2 negative as defined by ASCO/CAP criteria) * Must have a formalin fixed paraffin embedded tissue block (from primary or metastatic tumour) available and must have provided informed consent for the release of the block. * Presence of radiologically documented disease. * Measurable disease as defined by RECIST 1.1. * ASPS participants ≥ 15 years of age. * TNBC and RCC participants ≥ 18 years of age. * ECOG performance status of 0 or 1 or Karnofsky or Lansky \> 60. * Anticipated life expectancy of ≥ 6 months. * Must have received prior systemic therapy as shown below; * ASPS - completed all systemic therapy available that has been shown to improve survival (unless contraindicated). * TNBC 1. Progressive disease following at least one line of systemic treatment for metastatic disease which must include an ADC (all participants) and an ICI (participants whose tumours express PD-L1). 2. ≤3 lines of treatment for metastatic disease. 3. Must have had at least 1 prior line of cytotoxic chemotherapy for breast cancer, in any setting, which must have included an anthracycline and a taxane (unless contraindicated). * RCC - must have progressive disease following at least one line of systemic treatment for metastatic disease that must have included an ICI and a VEGFR targeted agent (unless contraindicated). * Participants must have recovered to ≤ grade 1 from all reversible toxicity related to prior therapies. * Adequate washout must be followed per protocol. * Previous major surgery is permitted ≥21 days prior to enrollment * Prior external beam radiation is permitted ≥28 prior to enrollment. Concurrent radiotherapy is not permitted. * Adequate hematologic and biochemical parameters. * Consent and assent, when applicable, must be appropriately obtained in accordance with applicable local and regulatory requirements. Each participant or their parent/ legal guardian (if applicable) must sign a consent form prior to screening onto the trial to document their willingness to participate. * Fit for leukapheresis and has adequate venous access for cell collection. * Must be accessible for treatment and follow up at the participating centre for a minimum of 12 months or for as long as is deemed necessary by the treating physician. * Participants of childbearing potential must have agreed to use a highly effective contraceptive method. Exclusion criteria * Participants on active anticancer therapy for other advanced or metastatic malignancies. * Concurrent treatment with other anti-cancer therapy * Prior therapy with a gene therapy product or any adoptive T cell therapy or prior GPNMB targeting therapy. * Live attenuated vaccination administered within 30 days prior to or planned within 30 days after GCAR1 therapy. * Primary immunodeficiency or history of severe autoimmune disease (including: Crohn's disease, rheumatoid arthritis, systemic lupus) requiring immunosuppressive agents/ systemic disease modifying agents within 2 years of enrollment. * Active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the participant to be managed according to the protocol including but not limited to: * Hepatitis B or C virus (HBV or HCV). For participants with previous HBV or HCV infection who are currently on treatment, they are eligible if they have an undetectable viral load via quantitative PCR and/or nucleic acid testing * HIV positive by serology and PCR * Uncontrolled fungal, bacterial, viral or other infection * Current infection with HTLV-1 * Tuberculosis * Syphilis * West Nile Virus * Untreated and/or uncontrolled cardiovascular conditions and/or symptomatic cardiac dysfunction (including cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects) or unstable angina congestive heart failure or myocardial infarction within the previous year. * Known sensitivity or allergy to fludarabine, cyclophosphamide or any of their components, or to GCAR1 or any of its components. * Active intracerebral metastases or leptomeningeal disease. Participants who have received definitive treatment, are clinically stable and do not require corticosteroids are eligible to participate in the trial. * Pregnant or breastfeeding women.
Conditions Advanced Heart Failure, Advanced Non-Col...
Phase NA
Enrollment 400
Locations 5 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. It represents an adaption of the Mount Sinai PALLIATIVE CARE AT HOME (PC@H) program, which delivers home-based palliative care. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines. In Tier 1, patients who are able to care for themselves and no/mild symptoms receive a community health worker (CHW) trained to elicit illness understanding in a culturally competent way. In Tier 2, for patients with poorer function and mild symptoms, a social worker (SW), trained in serious illness communication, joins the CHW to further elicit patients' goals and prognostic understanding while communicating symptom needs to their primary clinician. In Tier 3, as function decreases and symptoms increase, an advance practice nurse (APN) joins the CHW and SW to manage complex symptoms. Finally, in Tier 4, for those older adults with the poorest function and most complex symptoms, a physician joins the team to ensure that the most complex needs (e.g., end-of-life treatment preferences and multifaceted symptom control) are met. The CHW follows patients longitudinally across all tiers and re-allocates them to the appropriate tier based on their evolving needs.

Design

Study type: Interventional Phases: Allocation: Randomized Intervention model: Parallel Primary purpose: Health Services Research Masking/blinding: Single

Interventions / Regimen

  • Behavioral: Tier-Palliative Care — TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines.
  • Behavioral: Community Health Worker — Usual Care plus the addition of a community health worker who will serve as a health coach for the participant.

Primary Outcomes

  • Edmonton Symptom Assessment Scale (ESAS) (12 months)
  • Functional Assessment of Chronic Illness Therapy-Palliative Care Scale (FACIT-Pal) (12 months)
  • Patient-reported goals of care discussion (12 months)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: NA
Status: Recruiting
Start Date: 2026-07-10
Completion: 2032-01-31
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 400 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Icahn School of Medicine at Mount Sinai
Collaborators: National Institute of Nursing Research (NINR)
Principal Investigators:
  • Laura Gelfman (PRINCIPAL_INVESTIGATOR) - Icahn School of Medicine at Mount Sinai
Contact Information
Study Contact:
Christian Espino
212-421-4632
Christian.Espino@mssm.edu
Laura Gelfman, MD, MPH
Laura.Gelfman@mssm.edu
Mount Sinai West
Laura Gelfman, MD, MPH
Laura.Gelfman@mssm.edu
Mount Sinai Hospital
Interventions
  • Behavioral: Tier-Palliative Care — TIER-PC is an adaptive model of delivering palliative care that provides the right level of care to the right patients at the right time. TIER-PC increases the number and intensity of disciplines added to the patient's care team as their symptoms worsen and function declines.
  • Behavioral: Community Health Worker — Usual Care plus the addition of a community health worker who will serve as a health coach for the participant.
Study Locations (5 sites)
Mount Sinai Queens, Astoria, New York 11102 United States
Mount Sinai Downtown, New York, New York 10003 United States
Mount Sinai West, New York, New York 10019 United States
Mount Sinai Morningside, New York, New York 10025 United States
Mount Sinai Hospital, New York, New York 10029 United States
Eligibility Criteria
Inclusion Criteria: * Advanced Heart Failure (HF) with two HF-related hospitalizations within the last 12 months or * Advanced lung or non-colorectal gastrointestinal cancer (pancreatic, gastric, hepatobiliary, small bowel, esophageal) or tripe negative breast cancer with one hospitalization within the last 6 months * KPS \> or = 50% (ECOG 0, 1 or 2) * \> 2 outpatient MSHS visits in prior 12 months * Manhattan or Queens residence * Capacity to provide informed consent * English or Spanish fluency * \> or = 18 years of age Exclusion Criteria: * Diagnoses of both cancer and advanced HF * Lung cancer with a driver mutation (e.g., EGFR) that confers a favorable prognosis and does not follow typical trajectory * Patients with \> 1 visit to Outpatient Supportive Oncology/Cardiology visit * Patients with last visit to Outpatient Supportive Oncology/Cardiology \< 3 months ago * Previous receipt of a ventricular assist device or previous heart transplantation * Receiving hospice care prior to study enrollment or enrolled in another study of a palliative care patient/caregiver intervention * Living in a facility (subacute rehab, long-term care facility, hospice facility or residence) * Callahan 6-Item Cognitive Screening score ≤3
Conditions Breast Cancer
Phase PHASE1
Enrollment 15
Locations 6 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

To evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects with HR-Positive/HER2-Negative solid tumor.

Design

Study type: Interventional Phases: Phase1 Allocation: Intervention model: Single Group Primary purpose: Treatment Masking/blinding: None

Interventions / Regimen

  • Drug: HRS-6209 Capsules and fulvestrant injection — HRS-6209, 100mg BID for 4 weeks, and single dose of fulvestrant injection

Primary Outcomes

  • Safety by reporting incidence and severity of Adverse events (graded as per CTCAE V5.0) of adverse events (AEs) and serious adverse events (SAEs), (Screening up to study completion,, an average of 1 year.)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: INTERVENTIONAL
Phase: PHASE1
Status: Recruiting
Start Date: 2026-05-15
Completion: 2027-11-10
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 15 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Atridia Pty Ltd.
Contact Information
Study Contact:
Kathy You
+61 02 9299 0433
kathyyou@atridia.com
Ravi Patel
+61 452 363 506
ravi.patel@atridia.com
Sarah Childs
Southern Highlands Private Hospital
Interventions
  • Drug: HRS-6209 Capsules and fulvestrant injection — HRS-6209, 100mg BID for 4 weeks, and single dose of fulvestrant injection
Study Locations (6 sites)
Southern Highlands Private Hospital, Bowral, New South Wales 2567 Australia
GenesisCare St Leonards, Sydney, New South Wales 2068 Australia
GenesisCare Frenchs Forest, Sydney, New South Wales 2086 Australia
Lyell McEwin Hospital, Elizabeth Vale, South Australia Australia
Ballarat Base Hospital, Ballarat, Victoria Australia
Frankston Hospital, Frankston, Victoria Australia
Eligibility Criteria
Inclusion Criteria 1. Ability to understand the trial procedures and possible adverse events, voluntarily participate in the trial. 2. Adequate bone marrow and other vital organ functions 3. Adequate liver function tests 4. HR-positive or HER2-negative solid tumor patients Exclusion Criteria 1. Plan to receive any other anti-tumor therapy during the study. 2. Active brain metastases . 3. Have poorly controlled or severe cardiovascular disease, including (1) congestive heart failure. 4. Previous use of fulvestrant 5. clinically significant endometrial abnormalities, including but not limited to endometrial hyperplasia and dysfunctional uterine bleeding. 6. With uncontrollable chronic systemic complications (such as severe chronic lung, liver, kidney, or heart disease). 7. With acute or active tuberculosis infection requiring medication. 8. Pregnant or lactating women, or females planning to become pregnant During the study. 9. Known history of clinically significant liver disease, untreated active hepatitis (hepatitis B, defined as hepatitis B virus surface antigen \[HBsAg\] or hepatitis B core antibody \[HBcAb\] positive
Conditions Mental Illness
Phase Not Applicable
Enrollment 90
Locations 1 sites
Compensation Not reported — ask the study team
Data Updated 2026-09-27
Study Details Design, interventions, and primary outcomes

About This Study

Mental illness is a major public health issue. It affects one in five people, represents the largest expense for health insurance (14%), is the leading cause of years lived with disability, and suicide is the main cause of death among people aged 15 to 35. Depression affects 15 to 20% of individuals at some point in their lives. Trauma-related disorders affect 4.6% of people, including 1- 2% with post-traumatic stress disorder (PTSD). Screening for mental health problems in primary care is crucial. It enables doctors to provide early treatment, reduces the need for emergency care, and decreases both the number and duration of hospital stays. However, general practitioners and other non-mental health professionals often report lacking the time, training, and tools to conduct such screenings. Fortunately, brief and validated screening tools exist in English: The PHQ-4 (Patient Health Questionnaire-4) for anxiety and depression, and the PC-PTSD-5 (Primary Care PTSD Screen for DSM-5) for PTSD. So far, no French versions of these tools have been validated.

Design

Study type: Observational Observational model: Cohort Time perspective: Prospective

Primary Outcomes

  • Assess the validity of the French version of the PHQ-4 (Patient Health Questionnaire-4 ) scale (14 days)
  • Assess the validity of the French version of the PC-TDSD-5 (Primary Care PTSD Screen for DSM-5) scale (14 days)
Interested in this trial?
Contact the study team directly or view the official listing
Study Information
Type: OBSERVATIONAL
Phase: Not Applicable
Status: Recruiting
Start Date: 2026-01-26
Completion: 2027-08-15
Eligibility
Age: 18 Years and older
Sex: ALL
Volunteers: false
Enrollment: 90 (ESTIMATED)
Sponsor & Investigators
Lead Sponsor: Assistance Publique - Hôpitaux de Paris
Contact Information
Study Contact:
Vladimir ADRIEN, Doctor
(+33) 1 48 95 59 37
vladimir.adrien@aphp.fr
Vladimir ADRIEN, Doctor
+33148955421
vladimir.adrien@aphp.fr
Hôpital Avicenne
Gaelle Colevray
gaellecolevray@gmail.com
Hôpital Avicenne
Interventions
N/A
Study Locations (1 sites)
Hôpital Avicenne, Bobigny, 93000 France
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years, * Outpatient or hospitalized for any health-related reason, * Oral and written proficiency in French, * Patient informed and willing to participate in the study, * Patient with health insurance coverage Exclusion Criteria: * Individuals under legal protection measures (guardianship, conservatorship, or legal supervision), * Other factors preventing obtaining non-opposition or conducting the research, such as: limited French proficiency, hearing impairment, or significant cognitive disorders